查詢結果分析
來源資料
相關文獻
- C型肝炎
- Assessment of Factors Correlated with Ribavirin Dose Reduction Due to Hemolytic Anemia during Treatment in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin Combination Therapy
- 慢性C型肝炎患者接受抗病毒藥物治療失敗之機轉及因應措施
- 慢性C型肝炎治療的新時代
- Falsely Low Hemoglobin A1c Values in Diabetic Patients Receiving Peginterferon-alpha and Ribavirin for Chronic Hepatitis C
- Efficacy of Peginterferon Alfa Plus Ribavirin Treatment for Chronic Hepatitis C Virus Infection in Cirrhotic Patients
- 合併感染C型肝炎及人類免疫不全病毒患者之評估與治療要點
- Successful Treatment with Peginterferon and Ribavirin in a Patient with Acute Hepatitis C Evolving into Chronicity
- C型肝炎病毒感染之細胞生物學、免疫控制及治療
- 慢性C型肝炎患者肝臟移植後病毒復發感染之狀況與治療
頁籤選單縮合
題名 | C型肝炎=Hepatitis C |
---|---|
作 者 | 文薜帷; 黃一城; 黃煜庭; | 書刊名 | 輔仁醫學期刊 |
卷期 | 11:1 2013.03[民102.03] |
頁次 | 頁29-38 |
分類號 | 415.5332 |
關鍵詞 | C型肝炎; 干擾素; 雷巴威林; Hepatitis C; Interferon; Ribavirin; |
語文 | 中文(Chinese) |
中文摘要 | C型肝炎是台灣常見的慢性肝炎,盛行率約為4.4%,但有明顯的地域差異。C型肝炎為核糖核酸病毒,在複製的過程中易發生突變。目前世界上有6種主要的基因型,以台灣來說,基因型第1型約佔53%,第2型約佔40%。成人的C型肝炎感染有很高的機會成為慢性肝炎,之後則會引起肝硬化及肝癌的併發症。治療C型肝炎目前仍以干擾素合併雷巴威林為主,而美國食品藥物管理局則已於去年通過直接作用型抗病毒藥物。隨著新藥的發展,C型肝炎的治療效果益佳,可望減少因C型肝炎導致的肝硬化及肝癌。 |
英文摘要 | Hepatitis C virus (HCV) infection is a frequent cause of chronic hepatitis in Taiwan. Its prevalence is about 4.4%, with great variations among different regions. The genome of the HCV is comprised of RNA, and there is a high mutation rate during replication. There are 6 major genotypes in the world, and the prevalence of genotype 1 in Taiwan is 53%, and that of genotype 2 is 40%. Infection with hepatitis C in adulthood results in a high chance of chronic infection, with the subsequent complications of cirrhosis and hepatoma. The main strategy of treatment encompasses a combination of interferon and ribavirin, and the US Food and Drug Administration approved direct acting antivirals in 2011. With the development of new medications, better treatment responses of chronic hepatitis C and hence declining cirrhosis and hepatoma due to chronic hepatitis C infection are expected. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。